Brepocitinib Overview & RVT-3101 Update

Brepocitinib VTAMA Psoriasis | Dermavant (tapinarof) cream 1% ✓✓ Atopic Dermatitis | Dermavant VTAMA (tapinarof) cream 1% RVT-3101 Ulcerative Colitis | New Vant RVT-3101 Crohn's Diseases | New Vant BREPOCITINIB Dermatomyositis | Priovant BREPOCITINIB Systemic Lupus Erythematosus | Priovant Modality Preclinical Phase 1 Phase 2 Phase 3 Approved Topical Topical Biologic Biologic Small Molecule Small Molecule BREPOCITINIB Other Indications | Priovant Small Molecule Y BATOCLIMAB Myasthenia Gravis | Immunovant Biologic BATOCLIMAB Thyroid Eye Disease | Immunovant Biologic BATOCLIMAB Chronic Inflammatory Demyelinating Polyneuropathy | Immunovant Biologic др BATOCLIMAB Graves' Disease | Immunovant Biologic Y BATOCLIMAB Warm Autoimmune Hemolytic Anemia | Immunovant Biologic Y IMVT-1402 Numerous Indications | Immunovant Biologic n NAMILUMAB Sarcoidosis | Kinevant Biologic RVT-2001 Transfusion-Dependent Anemia in Patients with Lower-Risk MDS | Hemavant roivant Pipeline reflects both ongoing clinical trials and expected upcoming trials. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis. Small Molecule A Represents registrational or potentially registrational trials 24 24 For investor audiences only

View entire presentation